{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wewers TM"],"funding":["Deutsche Forschungsgemeinschaft"],"pagination":["1853-1863"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8455271"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(8)"],"pubmed_abstract":["Soluble Fms-like tyrosine kinase (sFlt-1/sVEGFR1) is a naturally occurring antagonist of vascular endothelial growth factor (VEGF). Despite being a secreted, soluble protein lacking cytoplasmic and transmembrane domains, sFlt-1 can act locally and be protective against excessive microenvironmental VEGF concentration or exert autocrine functions independently of VEGF. Circulating sFlt-1 may indiscriminately affect endothelial function and the microvasculature of distant target organs. The clinical significance of excess sFlt-1 in kidney disease was first shown in preeclampsia, a major renal complication of pregnancy. However, circulating sFlt-1 levels appear to be increased in various diseases with varying degrees of renal impairment. Relevant clinical associations between circulating sFlt-1 and severe outcomes (<i>e.g.,</i> endothelial dysfunction, renal impairment, cardiovascular disease, and all-cause mortality) have been observed in patients with CKD and after kidney transplantation. However, sFlt-1 appears to be protective against renal dysfunction-associated aggravation of atherosclerosis and diabetic nephropathy. Therefore, in this study, we provide an update on sFlt-1 in several kidney diseases other than preeclampsia, discuss clinical findings and experimental studies, and briefly consider its use in clinical practice."],"journal":["Journal of the American Society of Nephrology : JASN"],"pubmed_title":["Circulating Soluble Fms-like Tyrosine Kinase in Renal Diseases Other than Preeclampsia."],"pmcid":["PMC8455271"],"funding_grant_id":["SE2824/3-1"],"pubmed_authors":["Pavenstadt H","Schulz A","Brand M","Nolte I","Wewers TM","Di Marco GS"],"additional_accession":[]},"is_claimable":false,"name":"Circulating Soluble Fms-like Tyrosine Kinase in Renal Diseases Other than Preeclampsia.","description":"Soluble Fms-like tyrosine kinase (sFlt-1/sVEGFR1) is a naturally occurring antagonist of vascular endothelial growth factor (VEGF). Despite being a secreted, soluble protein lacking cytoplasmic and transmembrane domains, sFlt-1 can act locally and be protective against excessive microenvironmental VEGF concentration or exert autocrine functions independently of VEGF. Circulating sFlt-1 may indiscriminately affect endothelial function and the microvasculature of distant target organs. The clinical significance of excess sFlt-1 in kidney disease was first shown in preeclampsia, a major renal complication of pregnancy. However, circulating sFlt-1 levels appear to be increased in various diseases with varying degrees of renal impairment. Relevant clinical associations between circulating sFlt-1 and severe outcomes (<i>e.g.,</i> endothelial dysfunction, renal impairment, cardiovascular disease, and all-cause mortality) have been observed in patients with CKD and after kidney transplantation. However, sFlt-1 appears to be protective against renal dysfunction-associated aggravation of atherosclerosis and diabetic nephropathy. Therefore, in this study, we provide an update on sFlt-1 in several kidney diseases other than preeclampsia, discuss clinical findings and experimental studies, and briefly consider its use in clinical practice.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-26T16:33:18.572Z","creation":"2025-04-06T15:12:53.316Z"},"accession":"S-EPMC8455271","cross_references":{"pubmed":["34155060"],"doi":["10.1681/asn.2020111579","10.1681/ASN.2020111579"]}}